Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

Oppenheimer Adjusts Price Target on BridgeBio Oncology Therapeutics to $16 | WAPE

Newsfiscal.ai

Oppenheimer Adjusts Price Target on BridgeBio Oncology Therapeutics to $16

Oct 20, 2026, 17:32 ET · Published

Article summary

Oppenheimer has lowered its price target for BridgeBio Oncology Therapeutics from $22 to $16 while maintaining an Outperform rating.

An excerpt from the original article.

Related companies

BridgeBio Oncology Therapeutics, Inc. Common StockBBOTView stock

Analyzed by WAPE AI.

Preparing English content…

Comments —

Comment

Loading comments…